Objective: To describe the authors' experience with the implementation of a multidisciplinary approach and use of fish oil emulsion (FOE) in the management of infants with short bowel syndrome (SBS) and parenteral nutrition-associated liver disease (PNALD).
Methods: Between August 2006 and June 2009, four cases of SBS and severe PNALD were managed by the team using specifically developed protocols. The FOE was initiated if serum direct bilirubin levels were ≥100 µmol/L. To quantify the degree of exposure to high serum direct bilirubin levels over time, the area under the curve (AUC) for each patient was calculated before and after initiation of FOE. Linear regression analyses were performed to evaluate correlations between the AUC, duration of cholestasis and initiation of FOE.
Results: All patients survived and no complications were observed during the study period. After the first patient, FOE was initiated progressively earlier, but poor correlation between the AUC before and after its introduction was observed (r(2)=0.41924). However, there was strong correlation between the duration of PNALD before FOE initiation and time to resolution (r(2)=0.72133): the earlier the FOE was initiated, the shorter the time to resolution.
Conclusion: The authors report a positive experience with the implementation of a multidisciplinary approach and the use of FOE in infants with SBS and severe PNALD. The earlier the FOE was initiated during the cholestatic process, the shorter the time to resolution. The present study is a hypothesis generator, raising the question of whether an earlier introduction of this particular therapy can effectively shorten the cholestasis process in these patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352843 | PMC |
http://dx.doi.org/10.1155/2012/571829 | DOI Listing |
Cureus
November 2024
Nephrology, SRM Medical College Hospital and Research Centre, Chennai, IND.
Catheter-related bloodstream infections (CRBSIs) add to the morbidity and mortality of hemodialysis patients. is an extremely resistant, gram-negative, non-lactose-fermenting nosocomial bacterium that contributes significantly to mortality and morbidity. This bacterium is predominantly associated with community-acquired pneumonia, bacteremia, eye afflictions, biliary sepsis, urinary tract infection, skin and soft tissue infection, and very rarely chronic enteritis with colonic ulcers.
View Article and Find Full Text PDFEpilepsia Open
December 2024
Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Curr Cancer Drug Targets
October 2024
Faculty of Health & Life Sciences, Management and Science University, Seksyen 13, 40100, Shah Alam, Selangor, Malaysia.
Cyclophosphamide is a precursor of alkylating nitrogen mustard and was initially claimed to have antineoplastic and immunosuppressive properties. However, the role of cyclo-phosphamide as an immune activator has also been reported, depending on the dosage used. The application of lower-dose cyclophosphamide has emerged as a potential approach to cancer treatment.
View Article and Find Full Text PDFJ Ethnopharmacol
January 2025
Tianjin Modern Innovation Chinese Medicine Technology Co., Ltd., Tianjin, 300380, China; Haihe Laboratory of Modern Chinese Medicine, Tianjin, 301617, China. Electronic address:
Ethnopharmacological Relevance: Rosa odorata Sweet var. gigantea (Coll. et Hemsl.
View Article and Find Full Text PDFMaedica (Bucur)
June 2024
Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Introduction: Most breast cancers require neoadjuvant chemotherapy and the response to primary systemic therapy (PST) is crucial for deciding on the surgical technique and predicting patient outcomes. However, chemotherapy also brings numerous side effects, with cardiovascular issues being some of the most significant, common and challenging to manage.
Case Presentation: We present the case of a 71-year-old woman diagnosed with stage T2N1M0 Luminal B breast cancer.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!